Phase I Study of GSK461364, a Specific and Competitive Polo-like Kinase 1 Inhibitor, in Patients with Advanced Solid MalignanciesDavid Olmos, Sarah P. Blagden, Douglas S. Barker et al.|Clinical Cancer Research|2011Cited by 168
Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancerRohini Sharma, Hani Gabra, John D. Graham et al.|British Journal of Cancer|2009Cited by 65
Immunohistochemical markers of the hypoxic response can identify malignancy in phaeochromocytomas and paragangliomas and optimize the detection of tumours with VHL germline mutationsDavid J. Pinato, Tricia Tan, Radha Ramachandran et al.|British Journal of Cancer|2012Cited by 50
Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinomaDavid J. Pinato, Rohini Sharma|British Journal of Cancer|2019Cited by 45
Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B DysfunctionClaudia Angela Maria Fulgenzi, Calogero Cammà, Andrea Napolitano et al.|JAMA Oncology|2024Cited by 37